Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,786
archived clinical trials in
Dermatology

Study of Selected X-linked Disorders: Goltz Syndrome
Pathogenesis of Focal Dermal Hypoplasia or Goltz Syndrome and Related Disorders
Status: Enrolling
Updated:  12/31/1969
Baylor College of Medicine
mi
from
Houston, TX
Study of Selected X-linked Disorders: Goltz Syndrome
Pathogenesis of Focal Dermal Hypoplasia or Goltz Syndrome and Related Disorders
Status: Enrolling
Updated: 12/31/1969
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
Potential Research Study Participant Registry
Potential Research Study Participant Registry
Status: Enrolling
Updated:  12/31/1969
University of California-Davis
mi
from
Sacramento, CA
Potential Research Study Participant Registry
Potential Research Study Participant Registry
Status: Enrolling
Updated: 12/31/1969
University of California-Davis
mi
from
Sacramento, CA
Click here to add this to my saved trials
A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents, and Young Adults
A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents and Young Adults
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents, and Young Adults
A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents and Young Adults
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Molecular Bases of Response to Copper Treatment in Menkes Disease, Related Phenotypes, and Unexplained Copper Deficiency
Molecular Bases of Response to Copper Treatment in Menkes Disease, Related Phenotypes, and Unexplained Copper Deficiency
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Molecular Bases of Response to Copper Treatment in Menkes Disease, Related Phenotypes, and Unexplained Copper Deficiency
Molecular Bases of Response to Copper Treatment in Menkes Disease, Related Phenotypes, and Unexplained Copper Deficiency
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas
Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas
Status: Enrolling
Updated:  12/31/1969
Center for Excellence in Eye Care
mi
from
Miami, FL
Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas
Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas
Status: Enrolling
Updated: 12/31/1969
Center for Excellence in Eye Care
mi
from
Miami, FL
Click here to add this to my saved trials
Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas
Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas
Status: Enrolling
Updated:  12/31/1969
TLC Laser Eye Center
mi
from
Rockville, MD
Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas
Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas
Status: Enrolling
Updated: 12/31/1969
TLC Laser Eye Center
mi
from
Rockville, MD
Click here to add this to my saved trials
Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas
Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas
Status: Enrolling
Updated:  12/31/1969
TLC Laser Eye Center
mi
from
Fairfax, VA
Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas
Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas
Status: Enrolling
Updated: 12/31/1969
TLC Laser Eye Center
mi
from
Fairfax, VA
Click here to add this to my saved trials
Miltefosine to Treat Mucocutaneous Leishmaniasis
Treatment of Mucocutaneous Leishmaniasis With Miltefosine
Status: Enrolling
Updated:  12/31/1969
for this treatment IND, each Physician will enter patients at his/her own facility. Below data is for Protocol central contact
mi
from
Bethesda, MD
Miltefosine to Treat Mucocutaneous Leishmaniasis
Treatment of Mucocutaneous Leishmaniasis With Miltefosine
Status: Enrolling
Updated: 12/31/1969
for this treatment IND, each Physician will enter patients at his/her own facility. Below data is for Protocol central contact
mi
from
Bethesda, MD
Click here to add this to my saved trials
Miltefosine to Treat Mucocutaneous Leishmaniasis
Treatment of Mucocutaneous Leishmaniasis With Miltefosine
Status: Enrolling
Updated:  12/31/1969
NIH
mi
from
Bethesda, MD
Miltefosine to Treat Mucocutaneous Leishmaniasis
Treatment of Mucocutaneous Leishmaniasis With Miltefosine
Status: Enrolling
Updated: 12/31/1969
NIH
mi
from
Bethesda, MD
Click here to add this to my saved trials
Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
Status: Enrolling
Updated:  12/31/1969
Stanford University
mi
from
Palo Alto, CA
Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
Status: Enrolling
Updated: 12/31/1969
Stanford University
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
Status: Enrolling
Updated:  12/31/1969
University of Colorado Health Sciences Ctr.
mi
from
Aurora, CO
Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
Status: Enrolling
Updated: 12/31/1969
University of Colorado Health Sciences Ctr.
mi
from
Aurora, CO
Click here to add this to my saved trials
Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
Status: Enrolling
Updated:  12/31/1969
University of Iowa
mi
from
Iowa City, IA
Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
Status: Enrolling
Updated: 12/31/1969
University of Iowa
mi
from
Iowa City, IA
Click here to add this to my saved trials
Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins University
mi
from
Baltimore, MD
Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
Status: Enrolling
Updated:  12/31/1969
Boston University Medical Center
mi
from
Boston, MA
Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
Status: Enrolling
Updated: 12/31/1969
Boston University Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
Status: Enrolling
Updated:  12/31/1969
University of Michigan
mi
from
Ann Arbor, MI
Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
Status: Enrolling
Updated: 12/31/1969
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
Status: Enrolling
Updated:  12/31/1969
University of Minnesota Medical Center
mi
from
Minneapolis, MN
Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
Status: Enrolling
Updated: 12/31/1969
University of Minnesota Medical Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
Status: Enrolling
Updated:  12/31/1969
Hospital for Special Surgery
mi
from
New York, NY
Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
Status: Enrolling
Updated: 12/31/1969
Hospital for Special Surgery
mi
from
New York, NY
Click here to add this to my saved trials
Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
Status: Enrolling
Updated:  12/31/1969
Columbia University
mi
from
New York, NY
Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
Status: Enrolling
Updated: 12/31/1969
Columbia University
mi
from
New York, NY
Click here to add this to my saved trials
Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
Status: Enrolling
Updated:  12/31/1969
Univ of Rochester Medical Center
mi
from
Rochester, NY
Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
Status: Enrolling
Updated: 12/31/1969
Univ of Rochester Medical Center
mi
from
Rochester, NY
Click here to add this to my saved trials
Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
Status: Enrolling
Updated:  12/31/1969
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
Status: Enrolling
Updated: 12/31/1969
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
Status: Enrolling
Updated:  12/31/1969
Ohio State University
mi
from
Columbus, OH
Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
Status: Enrolling
Updated: 12/31/1969
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
Status: Enrolling
Updated:  12/31/1969
Medical University of South Carolina
mi
from
Charleston, SC
Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
Status: Enrolling
Updated: 12/31/1969
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
Status: Enrolling
Updated:  12/31/1969
University of Texas Southwestern
mi
from
Dallas, TX
Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
Status: Enrolling
Updated: 12/31/1969
University of Texas Southwestern
mi
from
Dallas, TX
Click here to add this to my saved trials
Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
Status: Enrolling
Updated:  12/31/1969
The University of Texas, Houston
mi
from
Houston, TX
Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
Status: Enrolling
Updated: 12/31/1969
The University of Texas, Houston
mi
from
Houston, TX
Click here to add this to my saved trials
Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
Status: Enrolling
Updated:  12/31/1969
University of Utah
mi
from
Salt Lake City, UT
Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
Status: Enrolling
Updated: 12/31/1969
University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Study of Ambrisentan With Antifibrotic Agent Combination Therapy in Diffuse Systemic Sclerosis
An Open Label Study of Ambrisentan With Antifibrotic Agent Combination Therapy in Treatment of Diffuse Systemic Sclerosis
Status: Enrolling
Updated:  12/31/1969
University of Pennsylvania Health System
mi
from
Philadelphia, PA
Study of Ambrisentan With Antifibrotic Agent Combination Therapy in Diffuse Systemic Sclerosis
An Open Label Study of Ambrisentan With Antifibrotic Agent Combination Therapy in Treatment of Diffuse Systemic Sclerosis
Status: Enrolling
Updated: 12/31/1969
University of Pennsylvania Health System
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas (2)
Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas
Status: Enrolling
Updated:  12/31/1969
Clear View Eye & Laser Medical Center
mi
from
San Diego, CA
Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas (2)
Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas
Status: Enrolling
Updated: 12/31/1969
Clear View Eye & Laser Medical Center
mi
from
San Diego, CA
Click here to add this to my saved trials
Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas (2)
Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas
Status: Enrolling
Updated:  12/31/1969
Corneal Consultants of Colorado, P.C
mi
from
Littleton, CO
Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas (2)
Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas
Status: Enrolling
Updated: 12/31/1969
Corneal Consultants of Colorado, P.C
mi
from
Littleton, CO
Click here to add this to my saved trials
Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas (2)
Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas
Status: Enrolling
Updated:  12/31/1969
Chicago Cornea Consultants, LTD
mi
from
Hoffman Estates, IL
Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas (2)
Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas
Status: Enrolling
Updated: 12/31/1969
Chicago Cornea Consultants, LTD
mi
from
Hoffman Estates, IL
Click here to add this to my saved trials
Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas (2)
Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas
Status: Enrolling
Updated:  12/31/1969
Minnesota Eye Consultants
mi
from
Bloomington, MN
Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas (2)
Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas
Status: Enrolling
Updated: 12/31/1969
Minnesota Eye Consultants
mi
from
Bloomington, MN
Click here to add this to my saved trials
Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas (2)
Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas
Status: Enrolling
Updated:  12/31/1969
Cornea Associates of Texas
mi
from
Dallas, TX
Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas (2)
Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas
Status: Enrolling
Updated: 12/31/1969
Cornea Associates of Texas
mi
from
Dallas, TX
Click here to add this to my saved trials
Corneal Collagen Crosslinking and Intacs for Keratoconus and Ectasia
Randomized Study of Safety and Effectiveness of Corneal Collagen Crosslinking and Intacs for Treatment of Keratoconus and Corneal Ectasia
Status: Enrolling
Updated:  12/31/1969
Cornea & Laser Eye Institute
mi
from
Teaneck, NJ
Corneal Collagen Crosslinking and Intacs for Keratoconus and Ectasia
Randomized Study of Safety and Effectiveness of Corneal Collagen Crosslinking and Intacs for Treatment of Keratoconus and Corneal Ectasia
Status: Enrolling
Updated: 12/31/1969
Cornea & Laser Eye Institute
mi
from
Teaneck, NJ
Click here to add this to my saved trials
Using High Resolution Function Imaging To Detect Melanoma and Dysplastic Nevi
Using High Resolution Function Imaging To Detect Melanoma and Dysplastic Nevi
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins Medicine
mi
from
Baltimore, MD
Using High Resolution Function Imaging To Detect Melanoma and Dysplastic Nevi
Using High Resolution Function Imaging To Detect Melanoma and Dysplastic Nevi
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins Medicine
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Pilot Study Using Anakinra/Kineret for the Treatment of Patients With Severe Atopic Dermatitis
A Pilot Study Using Anakinra/Kineret for the Treatment of Patients With Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
A Pilot Study Using Anakinra/Kineret for the Treatment of Patients With Severe Atopic Dermatitis
A Pilot Study Using Anakinra/Kineret for the Treatment of Patients With Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Corneal Crosslinking in Patients With Keratoconus and Post-Refractive Ectasia
Evaluation of Two Riboflavin Dosing Regimens for Corneal Collagen Cross-Linking in Eyes With Progressive Keratoconus or Ectasia
Status: Enrolling
Updated:  12/31/1969
Price Vision Group
mi
from
Indianapolis, IN
Corneal Crosslinking in Patients With Keratoconus and Post-Refractive Ectasia
Evaluation of Two Riboflavin Dosing Regimens for Corneal Collagen Cross-Linking in Eyes With Progressive Keratoconus or Ectasia
Status: Enrolling
Updated: 12/31/1969
Price Vision Group
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Corneal Collagen Crosslinking for Progressive Keratoconus and Ectasia Using Riboflavin/Dextran and Hypotonic Riboflavin
Corneal Collagen Crosslinking for Progressive Keratoconus and Ectasia Using Riboflavin/Dextran and Hypotonic Riboflavin
Status: Enrolling
Updated:  12/31/1969
Cornea & Laser Eye Institute
mi
from
Teaneck, NJ
Corneal Collagen Crosslinking for Progressive Keratoconus and Ectasia Using Riboflavin/Dextran and Hypotonic Riboflavin
Corneal Collagen Crosslinking for Progressive Keratoconus and Ectasia Using Riboflavin/Dextran and Hypotonic Riboflavin
Status: Enrolling
Updated: 12/31/1969
Cornea & Laser Eye Institute
mi
from
Teaneck, NJ
Click here to add this to my saved trials
Is Cryosurgery or Curettage More Effective at Treating Seborrheic Keratoses?
Is Cryosurgery or Curettage More Effective at Treating Seborrheic Keratoses?
Status: Enrolling
Updated:  12/31/1969
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Is Cryosurgery or Curettage More Effective at Treating Seborrheic Keratoses?
Is Cryosurgery or Curettage More Effective at Treating Seborrheic Keratoses?
Status: Enrolling
Updated: 12/31/1969
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Cross-linking of Corneal Collagen (CXL) With Ultraviolet-A in Asymmetric Corneas
Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas
Status: Enrolling
Updated:  12/31/1969
Schwartz Laser Eye Center
mi
from
Scottsdale, AZ
Cross-linking of Corneal Collagen (CXL) With Ultraviolet-A in Asymmetric Corneas
Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas
Status: Enrolling
Updated: 12/31/1969
Schwartz Laser Eye Center
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Cross-linking of Corneal Collagen (CXL) With Ultraviolet-A in Asymmetric Corneas
Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas
Status: Enrolling
Updated:  12/31/1969
Harvard Eye Associates
mi
from
Laguna Hills, CA
Cross-linking of Corneal Collagen (CXL) With Ultraviolet-A in Asymmetric Corneas
Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas
Status: Enrolling
Updated: 12/31/1969
Harvard Eye Associates
mi
from
Laguna Hills, CA
Click here to add this to my saved trials
Cross-linking of Corneal Collagen (CXL) With Ultraviolet-A in Asymmetric Corneas
Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas
Status: Enrolling
Updated:  12/31/1969
Clear View Eye & Laser Medical Center
mi
from
San Diego, CA
Cross-linking of Corneal Collagen (CXL) With Ultraviolet-A in Asymmetric Corneas
Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas
Status: Enrolling
Updated: 12/31/1969
Clear View Eye & Laser Medical Center
mi
from
San Diego, CA
Click here to add this to my saved trials
Cross-linking of Corneal Collagen (CXL) With Ultraviolet-A in Asymmetric Corneas
Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
San Francisco, CA
Cross-linking of Corneal Collagen (CXL) With Ultraviolet-A in Asymmetric Corneas
Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
San Francisco, CA
Click here to add this to my saved trials
Cross-linking of Corneal Collagen (CXL) With Ultraviolet-A in Asymmetric Corneas
Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas
Status: Enrolling
Updated:  12/31/1969
Davidorf Eye Group
mi
from
West Hills, CA
Cross-linking of Corneal Collagen (CXL) With Ultraviolet-A in Asymmetric Corneas
Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas
Status: Enrolling
Updated: 12/31/1969
Davidorf Eye Group
mi
from
West Hills, CA
Click here to add this to my saved trials
Cross-linking of Corneal Collagen (CXL) With Ultraviolet-A in Asymmetric Corneas
Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas
Status: Enrolling
Updated:  12/31/1969
Corneal Consultants of Colorado, P.C
mi
from
Littleton, CO
Cross-linking of Corneal Collagen (CXL) With Ultraviolet-A in Asymmetric Corneas
Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas
Status: Enrolling
Updated: 12/31/1969
Corneal Consultants of Colorado, P.C
mi
from
Littleton, CO
Click here to add this to my saved trials
Cross-linking of Corneal Collagen (CXL) With Ultraviolet-A in Asymmetric Corneas
Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas
Status: Enrolling
Updated:  12/31/1969
Center for Excellence in Eye Care
mi
from
Miami, FL
Cross-linking of Corneal Collagen (CXL) With Ultraviolet-A in Asymmetric Corneas
Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas
Status: Enrolling
Updated: 12/31/1969
Center for Excellence in Eye Care
mi
from
Miami, FL
Click here to add this to my saved trials
Cross-linking of Corneal Collagen (CXL) With Ultraviolet-A in Asymmetric Corneas
Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas
Status: Enrolling
Updated:  12/31/1969
Chicago Cornea Consultants, LTD
mi
from
Hoffman Estates, IL
Cross-linking of Corneal Collagen (CXL) With Ultraviolet-A in Asymmetric Corneas
Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas
Status: Enrolling
Updated: 12/31/1969
Chicago Cornea Consultants, LTD
mi
from
Hoffman Estates, IL
Click here to add this to my saved trials
Cross-linking of Corneal Collagen (CXL) With Ultraviolet-A in Asymmetric Corneas
Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas
Status: Enrolling
Updated:  12/31/1969
TLC Laser Eye Center
mi
from
Rockville, MD
Cross-linking of Corneal Collagen (CXL) With Ultraviolet-A in Asymmetric Corneas
Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas
Status: Enrolling
Updated: 12/31/1969
TLC Laser Eye Center
mi
from
Rockville, MD
Click here to add this to my saved trials
Cross-linking of Corneal Collagen (CXL) With Ultraviolet-A in Asymmetric Corneas
Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas
Status: Enrolling
Updated:  12/31/1969
Talamo Laser Eye Center
mi
from
Waltham, MA
Cross-linking of Corneal Collagen (CXL) With Ultraviolet-A in Asymmetric Corneas
Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas
Status: Enrolling
Updated: 12/31/1969
Talamo Laser Eye Center
mi
from
Waltham, MA
Click here to add this to my saved trials
Cross-linking of Corneal Collagen (CXL) With Ultraviolet-A in Asymmetric Corneas
Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas
Status: Enrolling
Updated:  12/31/1969
South Shore Eye Care LLP
mi
from
Wantagh, NY
Cross-linking of Corneal Collagen (CXL) With Ultraviolet-A in Asymmetric Corneas
Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas
Status: Enrolling
Updated: 12/31/1969
South Shore Eye Care LLP
mi
from
Wantagh, NY
Click here to add this to my saved trials
Cross-linking of Corneal Collagen (CXL) With Ultraviolet-A in Asymmetric Corneas
Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas
Status: Enrolling
Updated:  12/31/1969
TLC Laser Eye Center
mi
from
Fairfax, VA
Cross-linking of Corneal Collagen (CXL) With Ultraviolet-A in Asymmetric Corneas
Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas
Status: Enrolling
Updated: 12/31/1969
TLC Laser Eye Center
mi
from
Fairfax, VA
Click here to add this to my saved trials